Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2009

View Archived Issues

MicroDose Therapeutx acquires investigational RSV therapeutics from ViroPharma

Antisoma presents update on its clinical development activities

CEM-101 active against drug-resistant S. pneumoniae isolates from 3 continents

Benefit of PRX-032 in benign prostatic hyperplasia lasts at least one year

Phase III H5N1 vaccine safe and strongly immunogenic

ErbB4 gene variation linked to paliperidone response in schizophrenia patients

TMC-435 retreatment successful in HCV patients

Vernalis provides update on its clinical development activities

European Commission grants orphan drug status to MolMed's NGR-hTNF in HCC

Genfit to utilize stem cell research and targeting of nuclear receptors

Novo Nordisk reports results from third quarter of 2009

INX-189 exhibits anti-HCV activity in vitro and extensive liver delivery in vivo

HIV infection therapeutic TBR-652 shows good PK and safety profile in healthy subjects

Mintek claims novel compounds as apoptosis inducers for cancer treatment

Orexin receptor antagonists reported by Roche for the treatment of sleep disorders

Novel GR agonists for the treatment of asthma discovered by AstraZeneca

Glenmark describes CB1 and CB2 receptor ligands for the treatment of obesity

Shire reports results from emotional lability analysis in pediatric ADHD patients on Vyvanse

Adolor initiates testing in opioid bowel dysfunction program

Optimer completes enrollment in second phase III fidaxomicin trial

Abbott acquires novel investigational antibody for chronic pain

LEO Pharma acquires Peplin

NicOx reports results from phase Ib study of cholesterol-lowering agent NCX-6560

Transgene initiates enrollment into phase I trial of TG-4023 for liver cancer

BioInvent and Daiichi Sankyo to collaborate in the discovery of therapeutic antibodies

Synergy to fund phase IIa clinical trial of SP-304 for treatment of chronic constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...